NorthWest Biotherapeutics Inc (NWBO)

[GermanCol]

That is not true, they both show OS as primary end point, and most importantly, comparable to contemporaneous trials who received standard of care therapy only:

E.2.1 Main objective of the trial: The primary objective of this study is to compare overall survival (OS) between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma. This endpoint will be assessed using 3 different analyses

E.5.1 Primary end point(s): The primary endpoint of this study is overall survival (OS) compared between patients randomized to DCVax-L and control patients from comparable, contemporaneous trials who received standard of care therapy only, in patients with newly diagnosed glioblastoma.

https://www.clinicaltrialsregister.eu/ctr-search/search?query=DCVAX